

BioLight Announces the Formation of Scientific Advisory Board (SAB)

BioLight’s SAB, comprising of global key opinion leaders and business leaders in the field of Ophthalmology will support the continued success of BioLight by providing advice with respect to Company’s current portfolio and new investments.

BioLight Life Sciences Ltd, is pleased to announce the formation of its new Scientific Advisory Board (SAB). The SAB committee team is composed of highly qualified, internationally recognized scientific, medical experts and business key opinion leaders in the field of ophthalmology.

“SAB members contribution to applied innovations in the field of ophthalmology together with their broad range of expertise will support the continued success of BioLight. Our New SAB will help us to support our current portfolio in their strategic decisions and will assist us to invest in the cutting-edge new technologies presented to us. The mix of ophthalmic key opinion leaders, researchers and top management represents our vision of the need to bring to the market the most innovative and must have technologies in ophthalmology” said Yaacov Michlin, CEO of BioLight Life Sciences.

The new SAB is currently comprised of following members: (listed in alphabetical order)

Dr. Vincente Anido Jr. is a world-renowned ophthalmology industry leader. In his recent role he served as the CEO and Chairman of the Board of Aerie pharmaceuticals, an ophthalmic pharmaceutical company [NASDAQ: AERI]. Prior to Aerie, he led several companies including in his role as the CEO of ISTA Pharmaceuticals, that was acquired by Bausch + Lomb. He holds a B.S. and a M.S. from West Virginia University and a Ph.D. from the University of Missouri, Kansas City. Dr. Anido Jr. is also nominated as Special Strategic Advisor of ViSci Ltd., a subsidiary of BioLight.



Dr. Vincente Anido Jr

Dr. Jeffrey Goldberg is a Professor and Chair of Ophthalmology at the Byers Eye Institute at Stanford University. His research is directed at neuroprotection and regeneration of retinal ganglion cells and the optic nerve. Dr. Goldberg is also the co-founder of Peripherex, one of BioLight’s portfolio companies engaged in solutions for remote diagnosis of peripheral vision impairment. Dr. Goldberg received his B.S. magna cum laude from Yale University, and his M.D. and Ph.D. from Stanford University where he made significant discoveries about the failure of optic nerve regeneration.



Dr. Jeffrey Goldberg

Professor Anat Loewenstein is the Chairwoman of the Department of Ophthalmology at Ichilov Sourasky Medical Center Tel Aviv, the leading center for diagnosing and treating a complete spectrum of ophthalmological diseases and Chairwoman of the Israeli Ophthalmological Society. She also serves as Vice Dean of the Faculty of Medicine, and Sidney Fox Chair of Ophthalmology at the Sackler Faculty of Medicine at the Tel Aviv University. Anat is involved in numerous leading ophthalmic companies (such as Notal Vision) in various roles.



Professor Anat Loewenstein

Dr. Ron Neumann, BioLight's Chief Medical Officer (CMO), is a leading expert ophthalmologist, specializing in inflammatory eye disease. He has served as a Chief Fellow at the Harvard University's Eye and Ear Infirmary, established a Clinic for Inflammatory Eye Diseases at Sheba Medical Hospital and has held various senior positions including serving as the Global Medical Director for Teva Pharmaceuticals of Innovative Products. Dr Neumann serves as a special consultant in inflammatory eye disease to Maccabi; Israel's leading HMO.



Dr. Ron Neumann

Dr. Joseph Tauber, is an internationally recognized authority in the field of ocular surface diseases. He has been a Principal Investigator in dozens of clinical research programs, including those that led to the approval of the only two medications approved by the FDA for the treatment of dry eye. Dr. Tauber received his doctorate from Harvard Medical School, his training in internal medicine at Beth Israel Hospital and in ophthalmology at Tufts-New England Medical Center.



Dr. Joseph Tauber

For additional information, please visit the Company's website at www.bio-light.co.il where you can review the Company's portfolio companies, TASE filings, press releases, announcements and events.

BioLight Life Sciences (BOLT – TASE) is a leading company investing in companies and managing projects in the field of ophthalmology, eye diseases and ocular treatments. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine designed to improve the efficacy and safety of treatments of eye diseases exemplifying the enormous potential of Israeli innovation in these fields.